Tyrosine kinase inhibitor for CML: all the same?

Lukas Veltmaat; Jorge Cortes

doi:10.1182/bloodadvances.2024014060

Tyrosine kinase inhibitor for CML: all the same?

Lukas Veltmaat
, Jorge Cortes

Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	5339-5341
Number of pages	3
Journal	Blood Advances
Volume	8
Issue number	20
DOIs	https://doi.org/10.1182/bloodadvances.2024014060
State	Published - Oct 22 2024

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/bloodadvances.2024014060

Cite this

@article{fe5447d56dff466c84a8587ead6f2849,

title = "Tyrosine kinase inhibitor for CML: all the same?",

author = "Lukas Veltmaat and Jorge Cortes",

year = "2024",

month = oct,

day = "22",

doi = "10.1182/bloodadvances.2024014060",

language = "English (US)",

volume = "8",

pages = "5339--5341",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "20",

}

TY - JOUR

T1 - Tyrosine kinase inhibitor for CML

T2 - all the same?

AU - Veltmaat, Lukas

AU - Cortes, Jorge

PY - 2024/10/22

Y1 - 2024/10/22

UR - https://www.scopus.com/pages/publications/85207859684

UR - https://www.scopus.com/pages/publications/85207859684#tab=citedBy

U2 - 10.1182/bloodadvances.2024014060

DO - 10.1182/bloodadvances.2024014060

M3 - Comment/debate

C2 - 39392647

AN - SCOPUS:85207859684

SN - 2473-9529

VL - 8

SP - 5339

EP - 5341

JO - Blood Advances

JF - Blood Advances

IS - 20

ER -

Tyrosine kinase inhibitor for CML: all the same?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this